Clinical trial

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

NCT03294577

Drugs and interventions used in this trial

4 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Mapped RxNorm record Pegfilgrastim Normalized identity: pegfilgrastimView linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Plinabulin Find medicine records · Find other trials using this name

OTHER · Unmapped registry intervention D5W Placebo Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Docetaxel, doxorubicin, and cyclophosphamide (TAC) Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Plinabulin vs. Pegfilgrastim in Prevention of TAC Induced Neutropenia

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE3

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2019-10-23

PhasePHASE3

Conditions

Chemotherapy-induced Neutropeniaunresolved

Interventions

PegfilgrastimDRUG · verified · RxNorm: pegfilgrastim

PlinabulinDRUG

D5W PlaceboOTHER

Docetaxel, doxorubicin, and cyclophosphamide (TAC)DRUG

Sponsors & collaborators

BeyondSpring Pharmaceuticals Inc.lead sponsor

Mapped research locations

KyivUkraine2 KharkivUkraine2 GuangzhouGuangdong, China1 ChangchunJilin, China1 LvivUkraine1 VinnytsiaUkraine1 OdesaUkraine1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03294577 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.